Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neuroblastoma 7Lymphoma, B-Cell 5Lymphoma 5Rhabdoid Tumor 3Neoplasms 3Medulloblastoma 3Leukemia, Myeloid, Acute 3Leukemia 3Sarcoma, Ewing 2Rhabdomyosarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pinealoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasms, Germ Cell and Embryonal 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Ganglioneuroblastoma 2Ependymoma 2Enteropathy-Associated T-Cell Lymphoma 2Brain Neoplasms 2Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Pyloric Stenosis, Hypertrophic 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1

Interventions

Vincristine 3Rituximab 3Prednisone 3Etoposide 3Doxorubicin 3Cyclophosphamide 3Filgrastim 2prednylidene 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1liposomal doxorubicin 1ibrutinib 1etoposide phosphate 1deltacortene 1Ultrasonography 1Lenalidomide 1Granulocyte Colony-Stimulating Factor 1Endoscopy 1Electrocardiography 1Echocardiography 1CT-P10 1Bronchoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, AIDS-Related × etoposide phosphate × 1 year × Clear all
NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
17 enrolled 21 charts
Lymphoid

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡